HGF: Hepatocyte growth factor
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on HGF, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Ficlatuzumab | Phase 3 | LG Chem | Antibody | InhibitorHepatocyte growth factor inhibitor | 2 |
| Rilotumumab | Phase 3 | Amgen | Antibody | InhibitorHepatocyte growth factor inhibitor | 0 |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Ficlatuzumab | Phase 3 | Recruiting | AVEO Pharmaceuticals, Inc. | Oct 3, 2023 |
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | Ficlatuzumab | Phase 2 / Phase 3 | Recruiting | Beat AML, LLC | Jan 9, 2017 |
- Hearing loss, autosomal recessive0.60
- Gastric adenocarcinoma0.41
- Gastroesophageal junction adenocarcinoma0.41
- Melanoma0.40
- Lung carcinoma0.40
- Cancer0.40
- Deafness0.40
- Esophageal adenocarcinoma0.39
- Lung adenocarcinoma0.39
- Gastric carcinoma0.38
- Prostate carcinoma0.38
- Neurodegenerative disease0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5479, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P14210, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets